Abstract: Cardiotoxicity, specifically left ventricular (LV) dysfunction, remains a significant concern in pediatric oncology. This review explores the historical evolution of understanding cancer treatment-associated LV dysfunction, its impact on clinical oncology practice, current diagnostic and therapeutic strategies, and future directions in research and management. We delve into the mechanisms of cancer-induced LV dysfunction, existing guidelines for its management, the critical role of LVEF monitoring, and the evolving landscape of treatment options for LV dysfunction in pediatric cancer survivors.
1. Cancer-Induced LV Dysfunction: A Historical Perspective
The recognition of cardiotoxicity as a potential consequence of cancer therapy dates back to the early days of chemotherapy. Initial reports focused primarily on anthracyclines, like doxorubicin, which were observed to cause dose-dependent cardiomyopathy. However, it quickly became apparent that other chemotherapeutic agents, radiation therapy, and even some targeted therapies could also contribute to LV dysfunction. Early studies relied heavily on echocardiography to assess LV function, often focusing solely on ejection fraction (LVEF). This limited approach, however, failed to capture the full spectrum of LV dysfunction, which can encompass abnormalities in systolic, diastolic, and global function.
The initial focus was understandably on minimizing cardiotoxicity by reducing drug dosages or employing cardioprotective strategies like dexrazoxane. However, this approach often resulted in compromised cancer treatment efficacy. The balance between achieving optimal cancer control and minimizing cardiac risk became, and remains, a crucial challenge in pediatric oncology. As our understanding of the pathophysiology of cancer-induced cardiotoxicity improved, so did the sophistication of diagnostic tools and therapeutic interventions.
2. Mechanisms of Cancer-Induced LV Dysfunction
The mechanisms underlying cancer-induced LV dysfunction are multifaceted and complex. They can be broadly categorized into direct and indirect effects:
* Direct Cardiotoxicity: Anthracyclines, for example, intercalate into DNA, inhibiting topoisomerase II and inducing oxidative stress within cardiomyocytes. This leads to cellular damage, apoptosis, and ultimately, impaired myocardial function. Other chemotherapeutic agents exert their cardiotoxic effects through different mechanisms, such as inhibition of mitochondrial function or disruption of calcium homeostasis. Radiation therapy can directly damage cardiac cells, leading to fibrosis and impaired contractility.
* Indirect Cardiotoxicity: Inflammation plays a significant role in the development of cardiotoxicity. Cancer itself, its treatment, and the resulting immunosuppression can trigger systemic inflammation, which can further damage the heart. Furthermore, several chemotherapy agents can affect endothelial function, leading to impaired coronary blood flow and myocardial ischemia. Finally, some chemotherapeutic agents can affect the autonomic nervous system, leading to alterations in heart rate and rhythm.
Understanding these complex mechanisms is crucial for developing effective preventative and therapeutic strategies. Research continues to explore the specific molecular pathways involved in cancer-induced cardiotoxicity, paving the way for targeted interventions.
3. Cancer-Induced LV Guidelines: A Multidisciplinary Approach
The management of cancer-induced LV dysfunction requires a multidisciplinary approach, involving oncologists, cardiologists, and other specialists. Several guidelines have been developed to provide recommendations for the prevention, diagnosis, and management of cardiotoxicity in pediatric cancer patients. These guidelines emphasize the importance of:
* Risk Stratification: Identifying patients at high risk for cardiotoxicity based on factors such as age, underlying cardiac conditions, cumulative doses of cardiotoxic agents, and the presence of other risk factors.
current url：https://fusaji.c425n.com/bag/lv-function-treatment-impacts-pediatric-cancer-abbreviated-76420